Trials / Withdrawn
WithdrawnNCT05821374
Deucravacitinib in PG
Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Dartmouth-Hitchcock Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | 6 mg tablet |
Timeline
- Start date
- 2024-04-29
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
- First posted
- 2023-04-20
- Last updated
- 2025-06-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05821374. Inclusion in this directory is not an endorsement.